Clinical Trial to Evaluate Safety and Efficacy of Jalosome® Soothing Gel.

Inclusion Criteria: * Male and female subject aged ≥18 years old. * Performance status 0-1. * Diagnosis of HNC (epithelial carcinoma of oropharynx, nasopharynx, larynx, hypopharynx, paranasal sinuses or salivary glands). * Postoperative or curative RT (total radiation dose of at least 60 Gy), with or without concurrent chemotherapy. * Willingness and ability to give informed consent and comply with study procedures. Exclusion Criteria: * Pregnant or lactating women. * Previous RT on the head and neck area. * Planned to receive concurrent cetuximab. * Cutaneous and/or connective diseases (i.e. lupus erythematosus or scleroderma). * Systemic diseases known to delay the skin healing process, such as diabetes mellitus or severe renal failure. * Use of a tissue-equivalent bolus. * Use of over-the-counter topical medications containing steroids. * Presence of rashes or unhealed wounds in the radiation field. * Recent sun exposure (\<1 month). * Mental conditions that could adversely affect subject's adherence to the study.